Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease
Figure 3
Effect of rosiglitazone
treatment on plasma levels of C-reactive protein (CRP) in patients with
diabetes and coronary artery disease after percutaneous coronary intervention.
Data are means ± SD. Control group, ; rosiglitazone (RSG)
group, .